Banco Bilbao Vizcaya Argentaria S.A. Has $7.77 Million Stock Holdings in Novo Nordisk A/S $NVO

Key Points

• Banco Bilbao Vizcaya Argentaria S.A. increased its stake in Novo Nordisk A/S by 12.6% during the 1st quarter, holding ~$7.77 million in shares after acquiring an additional 12,553 shares.
• Analysts have recently set varied price targets for Novo Nordisk A/S, with a current consensus target price of $81.00 and an average rating of "Hold."
• Novo Nordisk A/S announced a semi-annual dividend of $0.4119 per share, representing a yield of 240.0%, with the ex-dividend date set for August 18th.

Banco Bilbao Vizcaya Argentaria S.A. boosted its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 12.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 112,023 shares of the company's stock after buying an additional 12,553 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Novo Nordisk A/S were worth $7,770,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Copeland Capital Management LLC lifted its holdings in Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after buying an additional 255 shares in the last quarter. North Capital Inc. acquired a new position in Novo Nordisk A/S during the 1st quarter worth $27,000. Park Square Financial Group LLC bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at $29,000. Stone House Investment Management LLC bought a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at $30,000. Finally, Transce3nd LLC bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at $33,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Analysts Set New Price Targets

NVO has been the subject of several recent research reports. Hsbc Global Res cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 31st. TD Cowen dropped their target price on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating for the company in a research report on Tuesday. BNP Paribas Exane upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 target price for the company in a research report on Wednesday, August 13th. Barclays reiterated an "equal weight" rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Finally, UBS Group cut shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 5th. Three investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $81.00.

Novo Nordisk A/S Price Performance

NVO opened at $54.7420 on Wednesday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $139.74. The company has a fifty day simple moving average of $64.03 and a 200 day simple moving average of $69.92. The stock has a market cap of $244.42 billion, a P/E ratio of 15.04, a P/E/G ratio of 1.84 and a beta of 0.63.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to analysts' expectations of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. On average, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th will be issued a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date is Monday, August 18th. Novo Nordisk A/S's dividend payout ratio is 22.53%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.